Drug
90y Ibritumomab Tiuxetan
90y Ibritumomab Tiuxetan: highest development phase Phase 2, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| 90Y Ibritumomab tiuxetan NCT01493479 | Phase 2 | Follicular Lymphoma |
Latest
No recent events.
Follow 90y Ibritumomab Tiuxetan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.